QRxPharma is a pain drug developer. So far over 1,000 (bunion, knee and hip replacement) patients have used its lead product called MoxDuo IR (immediate release) in a post surgical setting with positive results being achieved.
QRxPharma hit a speed bump in June 2012 when it sought approval of MoxDuo from the regulator in the US. Following this announcement, the share price fell almost 70%.
QRX's CEO Dr John Holaday explains what happened with the regulator and what the next steps are to gain approval. An intriguing situation has unfolded.
View the latest research reports and market data on QRxPharma.
Print this page